<!-- Changed ON 09/24/2024 -->
<!-- Google Tag Manager -->
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
})(window,document,'script','dataLayer','GTM-T2DH393N');</script>
<!-- End Google Tag Manager -->





<HTML lang="en-US">
<HEAD>

<!-- From FOATemplate.txt -->



	<TITLE>PAR-25-329: Development of Medications to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)</TITLE>



<META NAME="description" CONTENT="NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Development of Medications to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional) PAR-25-329. NIDA">
<META NAME="Keywords" CONTENT="PAR-25-329: Development of Medications to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<link href="../guide_styles/css/bootstrap.min.css" rel="stylesheet">
<link href="../guide_styles/css/style.css" rel="stylesheet">
<link href="../guide_styles/css/FOAM_Style.css" rel="stylesheet">

</HEAD>

<BODY>



<div class="container">
	<div class="row">
		<div class="col-xs-12">


<body onload="initContent()">
	<div class="container">
		<div class="row">
				<div id="page-title" class="heading1" tabindex="0">Department of Health and Human Services</div>
			
				<div>

	
		
	
	
		
		

		<div data-element-id="220599" data-element-has-label="false" data-element-required="false" data-element-has-value="true" data-section-code="OI" data-element-type="TEXT">
			 <a id='_bookmark220599' tabindex='-1' aria-hidden='true'></a><a name="_Part 1. Overview Information"></a><h1>Part 1. Overview Information</h1>
		</div>

	
		
	
	
		
		
	<div class="row" data-index="2">
			<div class="col-md-4 datalabel" tabindex="0" data-element-id="220600" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="TEXT">
					<a id='_bookmark220600' tabindex='-1' aria-hidden='true'></a>Participating Organization(s) 
			</div>
		<div class=" col-md-8 datacolumn">
                <p>National Institutes of Health (<a href="http://www.nih.gov">NIH</a>)</p> 
		</div>
	</div>

	
		
	
	
		
		
	<div class="row" data-index="3">
		<div class="col-md-push-4 col-md-8 datacolumn">
                 
		</div>
	</div>

	
		
	
	
		
		
	<div class="row" data-index="4">
			<div class="col-md-4 datalabel" tabindex="0" data-element-id="220602" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="LINKED_ELEMENT">
					<a id='_bookmark220602' tabindex='-1' aria-hidden='true'></a>Components of Participating Organizations 
			</div>
		<div class=" col-md-8 datacolumn">
                <p>National Institute on Drug Abuse (<a href="https://www.drugabuse.gov/" target="_blank" rel="noreferrer">NIDA</a>) 
		</div>
	</div>

	
		
	
	
		
		
	<div class="row" data-index="5">
		<div class="col-md-push-4 col-md-8 datacolumn">
                 
		</div>
	</div>

	
		
	
	
		
		
	<div class="row" data-index="6">
			<div class="col-md-4 datalabel" tabindex="0" data-element-id="220604" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="LINKED_ELEMENT">
					<a id='_bookmark220604' tabindex='-1' aria-hidden='true'></a>Funding Opportunity Title 
			</div>
		<div class=" col-md-8 datacolumn">
                <span class="title">Development of Medications to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)</span> 
		</div>
	</div>

	
		
	
	
		
		
	<div class="row" data-index="7">
			<div class="col-md-4 datalabel" tabindex="0" data-element-id="220605" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="TEXT">
					<a id='_bookmark220605' tabindex='-1' aria-hidden='true'></a>Activity Code 
			</div>
		<div class=" col-md-8 datacolumn">
                <p><a href="//grants.nih.gov/grants/funding/ac_search_results.htm?text_curr=ug3&amp;Search.x=0&amp;Search.y=0&amp;Search_Type=Activity">UG3</a>/<a href="//grants.nih.gov/grants/funding/ac_search_results.htm?text_curr=uh3&amp;Search.x=0&amp;Search.y=0&amp;Search_Type=Activity">UH3</a> Exploratory/Developmental Phased Award Cooperative Agreement</p> 
		</div>
	</div>

	
		
	
	
		
		
	<div class="row" data-index="8">
			<div class="col-md-4 datalabel" tabindex="0" data-element-id="220606" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="LINKED_ELEMENT">
					<a id='_bookmark220606' tabindex='-1' aria-hidden='true'></a>Announcement Type 
			</div>
		<div class=" col-md-8 datacolumn">
                Reissue of 
	
	
    <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-22-200.html" target="_blank" rel="noreferrer">PAR-22-200</a>
    
	
	<br/> 
		</div>
	</div>

	
		
	
	
		
		
	<div class="row" data-index="9">
			<div class="col-md-4 datalabel" tabindex="0" data-element-id="220607" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="TEXT">
					<a id='_bookmark220607' tabindex='-1' aria-hidden='true'></a>Related Notices</div>
<div class="col-md-8 datacolumn">
  <ul>
  
<p> 
    <!--Start NOSI Link-->
    
    See <a href="https://grants.nih.gov/grants/guide/NOSIs_targetingList.cfm?GuideDocID=42236">
    Notices of Special Interest</a> associated with this funding opportunity
    
    <p></p>
    <!--End NOSI Link-->
</p><li><strong>April 4, 2024</strong>&nbsp;- Overview of Grant Application and Review Changes for Due Dates on or after January 25, 2025. See Notice <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-OD-24-084.html">NOT-OD-24-084</a>.&nbsp;</li><li><strong>August 31, 2022 </strong>- Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice&nbsp;<a href="https://grants.nih.gov/grants/guide/notice-files/not-od-22-198.html">NOT-OD-22-198</a>.</li><li><strong>August 5, 2022 </strong>- Implementation Details for the NIH Data Management and Sharing Policy. See Notice <a href="https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-189.html">NOT-OD-22-189</a>.</li></ul> 
		</div>
	</div>

	
		
	
	
		
		
	<div class="row" data-index="10">
			<div class="col-md-4 datalabel" tabindex="0" data-element-id="220608" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="LINKED_ELEMENT">
					<a id='_bookmark220608' tabindex='-1' aria-hidden='true'></a>Funding Opportunity Number (FON) 
			</div>
		<div class=" col-md-8 datacolumn">
                <span class="noticenum">PAR-25-329</span> 
		</div>
	</div>

	
		
	
	
		
		
	<div class="row" data-index="11">
			<div class="col-md-4 datalabel" tabindex="0" data-element-id="220609" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="LINKED_ELEMENT">
					<a id='_bookmark220609' tabindex='-1' aria-hidden='true'></a>Companion Funding Opportunity 
			</div>
		<div class=" col-md-8 datacolumn">
                None 
		</div>
	</div>

	
		
	
	
		
		
	<div class="row" data-index="12">
			<div class="col-md-4 datalabel" tabindex="0" data-element-id="220610" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="TEXT">
					<a id='_bookmark220610' tabindex='-1' aria-hidden='true'></a>Number of Applications 
			</div>
		<div class=" col-md-8 datacolumn">
                <p>See <a href="#_3._Additional_Information">Section III. 3. Additional Information on Eligibility</a>.</p> 
		</div>
	</div>

	
		
	
	
		
		
	<div class="row" data-index="13">
			<div class="col-md-4 datalabel" tabindex="0" data-element-id="220611" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="LINKED_ELEMENT">
					<a id='_bookmark220611' tabindex='-1' aria-hidden='true'></a>Assistance Listing Number(s) 
			</div>
		<div class=" col-md-8 datacolumn">
                93.279 
		</div>
	</div>

	
		
	
	
		
		
	<div class="row" data-index="14">
			<div class="col-md-4 datalabel" tabindex="0" data-element-id="220612" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="TEXT">
					<a id='_bookmark220612' tabindex='-1' aria-hidden='true'></a>Funding Opportunity Purpose 
			</div>
		<div class=" col-md-8 datacolumn">
                <p style="margin-left:0in;" data-suggestion-start-before="insertion:e04453e93759ca8f3feaae81fdd5f9602:TOWNSENDE_807">The National Institute on Drug Abuse (NIDA) seeks research for the discovery and development of medications to prevent and treat substance use disorders (SUDs) and overdose.</p><p style="margin-left:0in;">&nbsp;</p><p style="margin-left:0in;">&nbsp;The UG3/UH3 Phased Innovation Awards Cooperative Agreement funding mechanism involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases.</p><p style="margin-left:0px;">Application may include preclinical or clinical research studies that will have high impact and quickly yield the necessary results to advance closer to or to FDA approval. The compounds to be evaluated can be small molecules or biologic and may focus on the development of new chemical entities, new formulations of marketed medications available for other indications, or combinations of medications.</p><p style="margin-left:0px;">Through this funding opportunity, NIDA seeks to fast-track the discovery and development of medications to prevent and treat SUDs and overdose and to advance them in the FDA's pathway.</p> 
		</div>
	</div>

	
		
	
	
		
		
	<div class="row" data-index="15">
		<div class="col-md-push-4 col-md-8 datacolumn">
                <a id='_bookmark220613' tabindex='-1' aria-hidden='true'></a><p></p> 
		</div>
	</div>

	
		
	
	
		
		
	<div class="row" data-index="16">
			<div class="col-md-4 datalabel" tabindex="0" data-element-id="224840" data-element-required="true" data-element-has-value="true" data-section-code="OI" data-element-type="TEXT">
					<a id='_bookmark224840' tabindex='-1' aria-hidden='true'></a>Funding Opportunity Goal(s) 
			</div>
		<div class=" col-md-8 datacolumn">
                <p data-suggestion-start-before="insertion:ecb5717b5a1e50c6aa1bc9c8fde32b48a:MARKETONJ_640">To support basic, clinical, translational, and implementation research in the field of substance use. To develop new knowledge and approaches for the prevention, diagnosis, and treatment of drug use, misuse, and addiction, drug overdose, and related health outcomes, including HIV/AIDS.</p> 
		</div>
	</div>

	
		
	
	
		
		
		  <!--This variable defines that we need to start a new row. -->

		<div data-element-id="220614" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="KD" data-element-type="TEXT">
			 <a id='_bookmark220614' tabindex='-1' aria-hidden='true'></a><a name="_Key Dates"></a><h2>Key Dates</h2>
		</div>

	
		
	
	
		
		
	<div class="row" data-index="18">
			<div class="col-md-4 datalabel" tabindex="0" data-element-id="220615" data-element-required="true" data-element-has-value="true" data-section-code="KD" data-element-type="DATE">
					<a id='_bookmark220615' tabindex='-1' aria-hidden='true'></a>Posted Date 
			</div>
		<div class=" col-md-8 datacolumn">
                January 03, 2025 
		</div>
	</div>

	
		
	
	
		
		
	<div class="row" data-index="19">
			<div class="col-md-4 datalabel" tabindex="0" data-element-id="220616" data-element-required="true" data-element-has-value="true" data-section-code="KD" data-element-type="LINKED_ELEMENT">
					<a id='_bookmark220616' tabindex='-1' aria-hidden='true'></a>Open Date (Earliest Submission Date) 
			</div>
		<div class=" col-md-8 datacolumn">
                March 10, 2025 
		</div>
	</div>

	
		
	
	
		
		
	<div class="row" data-index="20">
			<div class="col-md-4 datalabel" tabindex="0" data-element-id="220617" data-element-required="true" data-element-has-value="true" data-section-code="KD" data-element-type="TEXT">
					<a id='_bookmark220617' tabindex='-1' aria-hidden='true'></a>Letter of Intent Due Date(s) 
			</div>
		<div class=" col-md-8 datacolumn">
                <p>30 days prior to submission date</p> 
		</div>
	</div>

	
		
	
	
		
		
		  <!--This variable defines that we need to start a new row. -->

		<div data-element-id="220618" data-element-has-label="false" data-element-required="false" data-element-has-value="true" data-section-code="KD" data-element-type="LINKED_ELEMENT">
			 <a id='_bookmark220618' tabindex='-1' aria-hidden='true'></a>
<table class="table table-bordered table-striped table-hover eraDataTable" id="keyDatesContentTable">
	<thead>
		<tr>
			<th scope="col" colspan="3" style="border:2px solid #bcbcbc;" class="text-center">Application Due Dates</th>
			<th scope="col" colspan="3" style="border:2px solid #bcbcbc;" class="text-center">Review and Award Cycles</th>
		</tr>
		<tr> 
			<th scope="col" style="width:16.66%;border-left:2px solid #bcbcbc;" class="text-center">New</th>
			<th scope="col" style="width:16.66%" class="text-center">Renewal / Resubmission / Revision (as allowed)</th>
			<th scope="col" style="width:16.66%;border-right:2px solid #bcbcbc;" class="text-center">AIDS - New/Renewal/Resubmission/Revision, as allowed</th>
			<th scope="col" style="width:16.66%" class="text-center">Scientific Merit Review</th>
			<th scope="col" style="width:16.66%" class="text-center">Advisory Council Review</th>
			<th scope="col" style="width:16.66%;border-right:2px solid #bcbcbc;" class="text-center">Earliest Start Date</th>
		</tr>	
	</thead>
	<tbody>
				<tr>
					<td>
							April 10, 2025 
					</td>
					<td>
							April 10, 2025
					</td>
					<td>
							April 10, 2025
					</td>
					<td>July 2025</td>
					<td>							October 2025

					</td>
					<td>December 2025</td>
				</tr>
				<tr>
					<td>
							August 11, 2025 
					</td>
					<td>
							August 11, 2025
					</td>
					<td>
							August 11, 2025
					</td>
					<td>November 2025</td>
					<td>							January 2026

					</td>
					<td>April 2026</td>
				</tr>
	</tbody>
</table>
		</div>

	
		
	
		
		

		<div data-element-id="220619" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="KD" data-element-type="TEXT">
			 
		</div>

	
		
	
	
		
		

		<div data-element-id="220620" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="KD" data-element-type="TEXT">
			 <a id='_bookmark220620' tabindex='-1' aria-hidden='true'></a><p>All applications are due by 5:00 PM local time of applicant organization.&nbsp;</p>

<p>Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.</p>
		</div>

	
		
		
		

		<div data-element-id="220621" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="KD" data-element-type="CHECKBOX">
			 
		</div>

	
		
	
		
		

		<div data-element-id="220622" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="KD" data-element-type="TEXT">
			 
		</div>

	
		
	
		
		

		<div data-element-id="220623" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="KD" data-element-type="TEXT">
			 
		</div>

	
		
	
		
		

		<div data-element-id="220624" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="KD" data-element-type="TEXT">
			 
		</div>

	
		
	
		
		

		<div data-element-id="220625" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="KD" data-element-type="TEXT">
			 
		</div>

	
		
	
	
		
		
	<div class="row" data-index="29">
			<div class="col-md-4 datalabel" tabindex="0" data-element-id="220626" data-element-required="true" data-element-has-value="true" data-section-code="KD" data-element-type="LINKED_ELEMENT">
					<a id='_bookmark220626' tabindex='-1' aria-hidden='true'></a>Expiration Date 
			</div>
		<div class=" col-md-8 datacolumn">
                August 12, 2025 
		</div>
	</div>

	
		
	
	
		
		
	<div class="row" data-index="30">
			<div class="col-md-4 datalabel" tabindex="0" data-element-id="220627" data-element-required="true" data-element-has-value="true" data-section-code="KD" data-element-type="TEXT">
					<a id='_bookmark220627' tabindex='-1' aria-hidden='true'></a>Due Dates for E.O. 12372  
			</div>
		<div class=" col-md-8 datacolumn">
                <p>Not Applicable</p> 
		</div>
	</div>

	
		
	
	
		
		
		  <!--This variable defines that we need to start a new row. -->
		  		<div class="heading4" tabindex="0" data-element-id="220628" data-element-required="true" data-element-has-value="true" data-section-code="KD" data-element-type="TEXT">
						<a id='_bookmark220628' tabindex='-1' aria-hidden='true'></a>Required Application Instructions 					
				</div>

		<div data-element-id="220628" data-element-has-label="true" data-element-required="true" data-element-has-value="true" data-section-code="KD" data-element-type="TEXT">
			 <p>It is critical that applicants follow the instructions in the Research (R) Instructions in the <a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=82400">How to Apply - Application Guide</a>, except where instructed to do otherwise (in this NOFO or in a Notice from <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11164">NIH Guide for Grants and Contracts</a>).</p><p>Conformance to all requirements (both in the Application Guide and the NOFO) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions.</p><p><strong>Applications that do not comply with these instructions may be delayed or not accepted for review.</strong></p>
		</div>

	
		
		
		
	<div id="tocDiv">
		
    


<style>
.assist_button {
    background-color: #4CAF50; /* Green */
    border: none;
    color: white;
    padding: 8px 16px;
    text-align: center;
    text-decoration: none;
    display: inline-block;
    font-size: 14px;
}
.important {
	color: #F00;
	font-weight: bold;
	font-size 14px;
	}
</style>








            <p>There are several options available to submit your application through Grants.gov to NIH and 
            Department of Health and Human Services partners. You <b>must</b> use one of these submission 
            options to access the application forms for this opportunity.</p>
            <ol>
            <li>Use the NIH ASSIST system to prepare, submit and track your application online.
            <form action="https://public.era.nih.gov/assist" method="post" target="new">
              <input type="submit" value="Apply Online Using ASSIST" name="button" class="assist_button" />
            </form>
            </li>
            <li>Use an institutional system-to-system (S2S) solution to prepare and submit your application 
            to Grants.gov and <a href="https://public.era.nih.gov/commons/">eRA Commons</a> to track your 
            application. Check with your institutional officials regarding availability. <br /><br /></li>
            
                
                <li>Use <a href="https://grants.gov/search-grants?oppStatuses=closed|archived|posted|forecasted&fon=PAR-25-329" target="_new">Grants.gov</a> 
                Workspace to prepare and submit your application and 
                <a href="http://public.era.nih.gov/commons/">eRA Commons</a> to track your application.</li>
                <br /><br />

		
    <div class="heading1" tabindex="0">Table of Contents</div>
		<div class="toc-link"><a href="#_Part 1. Overview Information">Part 1. Overview Information</a></div><div class="toc-link P_SingleIndent"><a href="#_Key Dates">Key Dates</a></div><div class="toc-link"><a href="#_Part 2. Full Text of Announcement">Part 2. Full Text of Announcement</a></div><div class="toc-link P_SingleIndent"><a href="#_Section I. Notice of Funding Opportunity Description">Section I. Notice of Funding Opportunity Description</a></div><div class="toc-link P_SingleIndent"><a href="#_Section II. Award Information">Section II. Award Information</a></div><div class="toc-link P_SingleIndent"><a href="#_Section III. Eligibility Information">Section III. Eligibility Information</a></div><div class="toc-link P_SingleIndent"><a href="#_Section IV. Application and Submission Information">Section IV. Application and Submission Information</a></div><div class="toc-link P_SingleIndent"><a href="#_Section V. Application Review Information">Section V. Application Review Information</a></div><div class="toc-link P_SingleIndent"><a href="#_Section VI. Award Administration Information">Section VI. Award Administration Information</a></div><div class="toc-link P_SingleIndent"><a href="#_Section VII. Agency Contacts">Section VII. Agency Contacts</a></div><div class="toc-link P_SingleIndent"><a href="#_Section VIII. Other Information">Section VIII. Other Information</a></div>
	</div><br/>

	
		
	
	
		
		

		<div data-element-id="220630" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="FOD" data-element-type="TEXT">
			 <a id='_bookmark220630' tabindex='-1' aria-hidden='true'></a><a name="_Part 2. Full Text of Announcement"></a><h1>Part 2. Full Text of Announcement</h1>
		</div>

	
		
	
	
		
		

		<div data-element-id="220631" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="FOD" data-element-type="TEXT">
			 <a id='_bookmark220631' tabindex='-1' aria-hidden='true'></a><a name="_Section I. Notice of Funding Opportunity Description"></a><h2>Section I. Notice of Funding Opportunity Description</h2>
		</div>

	
		
	
	
		
		

		<div data-element-id="220632" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="FOD" data-element-type="TEXT">
			 <a id='_bookmark220632' tabindex='-1' aria-hidden='true'></a><p style="margin-left:0in;"><strong>Background</strong></p><p style="margin-left:0in;">Drug overdose is the leading cause of accidental death in the United States, with an estimated 106,850 deaths in 2022. Deaths involving synthetic opioids other than methadone (primarily fentanyl), psychostimulants (primarily methamphetamine), and cocaine were estimated to be 71%, 33%, and 27%, respectively. Furthermore, 48% of the 2022 overdose deaths were attributed to a synthetic opioid and another substance (i.e., polysubstance overdose).</p><p style="margin-left:0in;">Although there are safe and effective pharmacotherapies to treat opioid use disorder (OUD) and to prevent/reverse overdose, their utility is impaired by inherent limitations of the medications combined with underutilization. Methadone and buprenorphine are approved by the FDA to treat OUD, but long-term efficacy and treatment adherence are sub-optimal. Naltrexone is approved by the FDA to prevent opioid use relapse in people with no physical dependence to opioids but initiation and adherence to treatment are low. Naloxone is approved to reverse opioid overdose, but it may precipitate opioid withdrawal, and its relatively short duration of action may put naloxone-rescued individuals at risk of a subsequent overdose or renarcotization. Lofexidine is FDA-approved for the treatment of opioid withdrawal in adults, but it is not approved to treat pregnant women or neonatal opioid withdrawal syndrome. Unfortunately, there are no FDA-approved medications to treat overdose or SUDs associated with stimulants, cannabis, benzodiazepines, or polysubstance use. Therefore, there is an urgent need to develop safe and effective medications to prevent and treat SUDs and overdose.</p><p style="margin-left:0in;">Advances in the understanding of SUDs&nbsp;and overdose provide new opportunities to improve the treatment of these disorders and may ultimately contribute to reducing the current drug overdose crisis. Some of these advances include the new findings of receptors, neurotransmitters, neuromodulators, and brain circuits associated with these disorders. These advances have led to a greater understanding of endogenous systems and well as risk/protective factors for the onset and progression of these disorders. Application of these findings has led to new targets, formulations, and delivery systems to be evaluated. Furthermore, advances in the development of biologics offer an opportunity to investigate vaccines and monoclonal antibodies for the prevention or treatment of SUDs&nbsp;and drug overdose. Therefore, multiple therapeutic approaches may be poised for the next step in the FDA approval process and concerted efforts are needed to advance these potential pharmacotherapies to approval.</p><p style="margin-left:0in;"><strong>Research Focus</strong></p><p style="margin-left:0in;">The National Institute on Drug Abuse (NIDA) seeks preclinical and clinical research studies that will have high impact and quickly yield the necessary results to advance candidate medications for SUD and overdose closer to FDA approval. Applications should focus on studying new chemical entities (NCEs), medications already marketed for other indications, biologics (e.g., vaccines, monoclonal antibodies), natural products, or combinations of medications.</p><p><u>Topics that are considered to be within the scope of this notice of funding opportunity (NOFO) include, but are not limited to:</u></p><p>Preclinical evaluation of new chemical entities at a preclinical or late preclinical IND-enabling stage;</p><ul><li>Early clinical evaluation of drug candidate at early clinical development stages: FIH, SAD/MAD, PK/PD, drug-drug interaction studies with morphine or cocaine, translational clinical studies in patient populations, testing the target for safety and early evidence of efficacy signal to de-risk further clinical development;</li><li>Repurposing of marketed medications that are used for a non-SUD indication can include: preclinical and clinical safety evaluation (drug-drug interaction studies with the drug of use / misuse); clinical translational studies in early phase of clinical development, and/or proof-of-concept (POC) study assessing the pharmacologically best dose, efficacy and safety endpoints for the drug&nbsp;in preparation for phase III;</li><li>Phase III clinical stage drug candidates can include clinical development plans with the preparations for an end of phase II meeting with the FDA and phase III development program studies layout, where, if needed, the FDA feedback could be incorporated.</li><li>Use of Artificial Intelligence/Machine Learning (AI/ML) tools for chemistry, preclinical, and clinical medications development for SUDs. For example, use of AI/ML for de novo design of new molecules, virtual screening and drug-drug interaction studies, or use of AI in clinical trial design/analysis, etc.</li></ul><p style="margin-left:0in;">There is particular interest in the development of compounds for:</p><ul><li>Prevention of initiation of SUDs</li><li>Prevention of progression of the severity of SUDs</li><li>Reduction of the dose of opioids analgesics</li><li>Improvement of SUD treatment adherence</li><li>Facilitation of opioid agonist discontinuation</li><li>Treatment of drug withdrawal</li><li>Treatment of neonatal drug withdrawal</li><li>Reduction of tolerance</li><li>Reduction of lethality of overdose</li><li>Reduction of overdose relapse</li><li>Reduction of the risk of substance-induced respiratory depression</li></ul><p style="margin-left:0in;"><strong>Applications Not Responsive to this NOFO</strong></p><p style="margin-left:0in;">The following types of studies are not responsive to this NOFO and will not be reviewed:</p><ul><li>Applications focusing solely on novel target identification/validation, generation of new animal models, development/testing of new human laboratory models</li><li>Applications focusing on mechanistic studies of the neurobiology of addiction</li><li>Applications that address alcohol as the only substance of use.</li></ul><p style="margin-left:0in;"><strong>Milestones</strong></p><p style="margin-left:0in;">Because the development of medications is likely to be high risk, grant applications must provide clear milestones to be accomplished at the end of the UG3 phase. It is anticipated that there will be attrition of some projects that do not meet the of milestones the UG3. Objective milestones of success and go/no-go rules for medications development progression will be required, and both should have quantitative criteria associated with them.</p><p style="margin-left:0in;"><strong>Some examples of Milestones include:</strong></p><p style="margin-left:0in;"><strong>Hit Identified</strong></p><p style="margin-left:0in;">Compound(s) identified, and confirmed, with at least micromolar affinity for the target and some selectivity vs. counter targets</p><p style="margin-left:0in;"><strong>Lead Identified</strong></p><p style="margin-left:0in;">Chemical structure identified that can serve as a starting point for SAR to improve potency, selectivity, and/or pharmacokinetic parameters</p><p style="margin-left:0in;"><strong>Candidate Identified</strong></p><p style="margin-left:0in;">Single compound identified with adequate affinity, selectivity, pharmacokinetic and toxicological properties to initiate advanced toxicology/safety/drug-drug interaction studies</p><p style="margin-left:0in;"><strong>IND accepted</strong></p><p style="margin-left:0in;">Investigational New Drug application submitted to FDA with no clinical-hold imposed by the FDA</p><p style="margin-left:0in;"><strong>Phase I SAD/MAD successfully completed</strong></p><p style="margin-left:0in;">Completion of initial single and multiple dose clinical studies with no significant medical safety or pharmacokinetic issues identified</p><p style="margin-left:0in;"><strong>Phase Ib Translational Clinical Study successfully completed</strong></p><p style="margin-left:0in;">Completion of initial clinical efficacy testing in patients with no significant medical safety issues identified and preliminary efficacy signal evidence</p><p style="margin-left:0in;"><strong>Phase II Clinical study successfully completed</strong></p><p style="margin-left:0in;">Completion of clinical studies in intermediate-size patient groups with safety and efficacy demonstrated</p><p style="margin-left:0in;"><strong>Phase III Clinical study(s) successfully completed</strong></p><p style="margin-left:0in;">Completion of clinical studies in large patient groups with safety and efficacy demonstrated.</p><p style="margin-left:0in;"><strong>FDA approval</strong></p><p style="margin-left:0in;">Compound is approved for marketing by the FDA</p><p style="margin-left:0in;"><strong>Special Considerations</strong></p><p>NIDA applicants are strongly encouraged to review the guidelines and adhere to the requirements applicable to their research listed in the <a href="https://gcc02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.drugabuse.gov%2Ffunding%2Fspecial-considerations-for-nida-funding&amp;data=05%7C01%7Cyvonne.walker%40nih.gov%7C2b30605ae50740cd31fb08dad6eab2e5%7C14b77578977342d58507251ca2dc2b06%7C0%7C0%7C638058600752895551%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&amp;sdata=RZWNDnsvUK%2BgiMQdFmQN7h9cG6ADsnh51v0XvRnqG6k%3D&amp;reserved=0">Special Considerations for NIDA Funding Opportunities and Awards</a>. Upon award, these considerations will be included in the Notice of Grant Award</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220634" data-element-has-label="false" data-element-required="false" data-element-has-value="true" data-section-code="FOD" data-element-type="TEXT">
			 <a id='_bookmark220634' tabindex='-1' aria-hidden='true'></a><p><strong></strong> &nbsp;</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220635" data-element-has-label="false" data-element-required="false" data-element-has-value="true" data-section-code="FOD" data-element-type="TEXT">
			 <a id='_bookmark220635' tabindex='-1' aria-hidden='true'></a><p>Investigators proposing NIH-defined clinical trials may refer to the <a href="https://researchmethodsresources.nih.gov/">Research Methods Resources</a> website for information about developing statistical methods and study designs.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220633" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="FOD" data-element-type="TEXT">
			 <a id='_bookmark220633' tabindex='-1' aria-hidden='true'></a><p>See <a href="#_Section_VIII._Other">Section VIII. Other Information</a> for award authorities and regulations.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220636" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="AI" data-element-type="TEXT">
			 <a id='_bookmark220636' tabindex='-1' aria-hidden='true'></a><a name="_Section II. Award Information"></a><h2>Section II. Award Information</h2>
		</div>

	
		
	
	
		
		
	<div class="row" data-index="40">
			<div class="col-md-4 datalabel" tabindex="0" data-element-id="220637" data-element-required="true" data-element-has-value="true" data-section-code="AI" data-element-type="TEXT">
					<a id='_bookmark220637' tabindex='-1' aria-hidden='true'></a>Funding Instrument 
			</div>
		<div class=" col-md-8 datacolumn">
                <p>Cooperative Agreement: A financial assistance mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this NOFO.</p> 
		</div>
	</div>

	
		
	
	
		
		
	<div class="row" data-index="41">
			<div class="col-md-4 datalabel" tabindex="0" data-element-id="220638" data-element-required="true" data-element-has-value="true" data-section-code="AI" data-element-type="LINKED_ELEMENT">
					<a id='_bookmark220638' tabindex='-1' aria-hidden='true'></a>Application Types Allowed 
			</div>
		<div class=" col-md-8 datacolumn">
                New
	<br>
	Resubmission
	<br>
	Revision
	<br> 
		</div>
	</div>

	
		
	
	
		
		
	<div class="row" data-index="43">
		<div class="col-md-push-4 col-md-8 datacolumn">
                <a id='_bookmark220640' tabindex='-1' aria-hidden='true'></a><p>The&nbsp;<a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11116">OER Glossary</a>&nbsp;and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.</p> 
		</div>
	</div>

	
		
	
	
		
		
	<div class="row" data-index="44">
			<div class="col-md-4 datalabel" tabindex="0" data-element-id="220641" data-element-required="false" data-element-has-value="true" data-section-code="AI" data-element-type="TEXT">
					<a id='_bookmark220641' tabindex='-1' aria-hidden='true'></a>Clinical Trial? 
			</div>
		<div class=" col-md-8 datacolumn">
                <p>Optional: Accepting applications that either propose or do not propose clinical trial(s).</p> 
		</div>
	</div>

	
		
	
	
		
		
	<div class="row" data-index="45">
		<div class="col-md-push-4 col-md-8 datacolumn">
                <a id='_bookmark220642' tabindex='-1' aria-hidden='true'></a><p><a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=82370">Need help determining whether you are doing a clinical trial?</a></p> 
		</div>
	</div>

	
		
	
	
		
		
	<div class="row" data-index="46">
			<div class="col-md-4 datalabel" tabindex="0" data-element-id="220643" data-element-required="true" data-element-has-value="true" data-section-code="AI" data-element-type="TEXT">
					<a id='_bookmark220643' tabindex='-1' aria-hidden='true'></a>Funds Available and Anticipated Number of Awards  
			</div>
		<div class=" col-md-8 datacolumn">
                <p>The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.</p> 
		</div>
	</div>

	
		
	
	
		
		
	<div class="row" data-index="47">
			<div class="col-md-4 datalabel" tabindex="0" data-element-id="220644" data-element-required="true" data-element-has-value="true" data-section-code="AI" data-element-type="TEXT">
					<a id='_bookmark220644' tabindex='-1' aria-hidden='true'></a>Award Budget 
			</div>
		<div class=" col-md-8 datacolumn">
                Application budgets are limited to $3&#x00a0;million per year for direct costs. 
		</div>
	</div>

	
		
	
	
		
		
	<div class="row" data-index="48">
			<div class="col-md-4 datalabel" tabindex="0" data-element-id="220645" data-element-required="true" data-element-has-value="true" data-section-code="AI" data-element-type="TEXT">
					<a id='_bookmark220645' tabindex='-1' aria-hidden='true'></a>Award Project Period 
			</div>
		<div class=" col-md-8 datacolumn">
                <p>The maximum period of support is 5&#x00a0;years.</p> 
		</div>
	</div>

	
		
	
	
		
		
		  <!--This variable defines that we need to start a new row. -->

		<div data-element-id="220646" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="AI" data-element-type="TEXT">
			 <a id='_bookmark220646' tabindex='-1' aria-hidden='true'></a><p>NIH grants policies as described in the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11120">NIH Grants Policy Statement</a> will apply to the applications submitted and awards made from this NOFO.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220647" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="EI" data-element-type="TEXT">
			 <a id='_bookmark220647' tabindex='-1' aria-hidden='true'></a><a name="_Section III. Eligibility Information"></a><h2>Section III. Eligibility Information</h2>
		</div>

	
		
	
	
		
		

		<div data-element-id="220648" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="EI" data-element-type="TEXT">
			 <a id='_bookmark220648' tabindex='-1' aria-hidden='true'></a><h4>1. Eligible Applicants</p>
		</div>

	
		
	
	
		
		
		  		<div class="heading4" tabindex="0" data-element-id="220649" data-element-required="true" data-element-has-value="true" data-section-code="EI" data-element-type="TEXT">
						<a id='_bookmark220649' tabindex='-1' aria-hidden='true'></a>Eligible Organizations 					
				</div>

		<div data-element-id="220649" data-element-has-label="true" data-element-required="true" data-element-has-value="true" data-section-code="EI" data-element-type="TEXT">
			 <p>Higher Education Institutions</p>

<ul>
	<li>Public/State Controlled Institutions of Higher Education</li>
	<li>Private Institutions of Higher Education</li>
</ul>

<p>The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:</p>

<ul>
	<li>Hispanic-serving Institutions</li>
	<li>Historically Black Colleges and Universities (HBCUs)</li>
	<li>Tribally Controlled Colleges and Universities (TCCUs)</li>
	<li>Alaska Native and Native Hawaiian Serving Institutions</li>
	<li>Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)</li>
</ul>

<p>Nonprofits Other Than Institutions of Higher Education</p>

<ul>
	<li>Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)</li>
	<li>Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)</li>
</ul>

<p>For-Profit Organizations</p>

<ul>
	<li>Small Businesses</li>
	<li>For-Profit Organizations (Other than Small Businesses)</li>
</ul>

<p>Local Governments</p>

<ul>
	<li>State Governments</li>
	<li>County Governments</li>
	<li>City or Township Governments</li>
	<li>Special District Governments</li>
	<li>Indian/Native American Tribal Governments (Federally Recognized)</li>
	<li>Indian/Native American Tribal Governments (Other than Federally Recognized).</li>
</ul>
		</div>

	
		
	
	
		
		

		<div data-element-id="220650" data-element-has-label="false" data-element-required="false" data-element-has-value="true" data-section-code="EI" data-element-type="TEXT">
			 <a id='_bookmark220650' tabindex='-1' aria-hidden='true'></a><p>Federal Government</p>

<ul>
	<li>Eligible Agencies of the Federal Government</li>
	<li>U.S. Territory or Possession</li>
</ul>
		</div>

	
		
	
	
		
		

		<div data-element-id="220651" data-element-has-label="false" data-element-required="false" data-element-has-value="true" data-section-code="EI" data-element-type="TEXT">
			 <a id='_bookmark220651' tabindex='-1' aria-hidden='true'></a><p>Other</p>

<ul>
	<li>Independent School Districts</li>
	<li>Public Housing Authorities/Indian Housing Authorities</li>
	<li>Native American Tribal Organizations (other than Federally recognized tribal governments)</li>
	<li>Faith-based or Community-based Organizations</li>
	<li>Regional Organizations</li>
	<li>Non-domestic (non-U.S.) Entities (Foreign Organizations).</li>
</ul>
		</div>

	
		
	
	
		
		

		<div data-element-id="220652" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="EI" data-element-type="TEXT">
			 
		</div>

	
		
	
	
		
		
		  		<div class="heading4" tabindex="0" data-element-id="220653" data-element-required="true" data-element-has-value="false" data-section-code="EI" data-element-type="TEXT">
						<a id='_bookmark220653' tabindex='-1' aria-hidden='true'></a>Foreign Organizations 					
				</div>

		<div data-element-id="220653" data-element-has-label="true" data-element-required="true" data-element-has-value="false" data-section-code="EI" data-element-type="TEXT">
			 
		</div>

	
		
		
		

		<div data-element-id="220654" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="EI" data-element-type="RADIO_BUTTON">
			 <a id='_bookmark220654' tabindex='-1' aria-hidden='true'></a><p class="Normal">Non-domestic (non-U.S.) Entities (Foreign Organizations) <strong>are </strong>eligible to apply.</p>
		</div>

	
		
		
		

		<div data-element-id="220655" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="EI" data-element-type="RADIO_BUTTON">
			 <a id='_bookmark220655' tabindex='-1' aria-hidden='true'></a><p>Non-domestic (non-U.S.) components of U.S. Organizations <strong>are </strong>eligible to apply.</p>
		</div>

	
		
		
		

		<div data-element-id="220656" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="EI" data-element-type="RADIO_BUTTON">
			 <a id='_bookmark220656' tabindex='-1' aria-hidden='true'></a><p>Foreign components, as <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11118">defined in the <em>NIH Grants Policy Statement</em></a>, <strong>are </strong>allowed.&#160;</p>
		</div>

	
		
	
	
		
		
		  		<div class="heading4" tabindex="0" data-element-id="220657" data-element-required="true" data-element-has-value="true" data-section-code="EI" data-element-type="TEXT">
						<a id='_bookmark220657' tabindex='-1' aria-hidden='true'></a>Required Registrations 					
				</div>

		<div data-element-id="220657" data-element-has-label="true" data-element-required="true" data-element-has-value="true" data-section-code="EI" data-element-type="TEXT">
			 <p><strong>Applicant Organizations</strong></p>

<p>Applicant organizations must complete and maintain the following registrations as described in the How to Apply-Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. Failure to complete registrations in advance of&nbsp; a due date is not a valid reason for a late submission, please reference the&nbsp;<a href="//grants.nih.gov/grants/guide/url_redirect.php?id=82423">NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications</a>.</p>

<ul>
	<li><a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=82390">System for Award Management (SAM) &ndash;</a> Applicants must complete and maintain an active registration, <strong>which requires renewal at least annually</strong>. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.

	<ul style="list-style-type:circle">
		<li><a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11176">NATO Commercial and Government Entity (NCAGE) Code</a> &ndash; Foreign organizations must obtain an NCAGE code (in lieu of a CAGE code) in order to register in SAM.</li>
		<li>Unique Entity Identifier (UEI) - A UEI is issued as part of the SAM.gov registration process. The same UEI must be used for all registrations, as well as on the grant application.</li>
	</ul>
	</li>
	<li><a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=11123">eRA Commons</a> - Once the unique organization identifier is established, organizations can register with eRA Commons in tandem with completing their&nbsp;Grants.gov registration; all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.</li>
	<li><a href="//grants.nih.gov/grants/guide/url_redirect.php?id=82300">Grants.gov</a> &ndash; Applicants must have an active SAM registration in order to complete the Grants.gov registration.</li>
</ul>

<p><strong>Program Directors/Principal Investigators (PD(s)/PI(s))</strong></p>

<p>All PD(s)/PI(s) must have an eRA Commons account. &nbsp;PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.</p>
		</div>

	
		
	
	
		
		
		  		<div class="heading4" tabindex="0" data-element-id="220658" data-element-required="true" data-element-has-value="true" data-section-code="EI" data-element-type="TEXT">
						<a id='_bookmark220658' tabindex='-1' aria-hidden='true'></a>Eligible Individuals (Program Director/Principal Investigator) 					
				</div>

		<div data-element-id="220658" data-element-has-label="true" data-element-required="true" data-element-has-value="true" data-section-code="EI" data-element-type="TEXT">
			 <p>Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. <p>For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the How to Apply- Application Guide.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220659" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="EI" data-element-type="TEXT">
			 
		</div>

	
		
	
	
		
		

		<div data-element-id="220660" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="EI" data-element-type="TEXT">
			 <a id='_bookmark220660' tabindex='-1' aria-hidden='true'></a><h4>2. Cost Sharing</h4><p>This NOFO does not require cost sharing as defined in the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11126">NIH Grants Policy Statement Section 1.2 Definition of Terms</a>.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220661" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="EI" data-element-type="TEXT">
			 <a id='_bookmark220661' tabindex='-1' aria-hidden='true'></a><h4>3. Additional Information on Eligibility</h4><p>Number of Applications</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220662" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="EI" data-element-type="TEXT">
			 <a id='_bookmark220662' tabindex='-1' aria-hidden='true'></a><p>Applicant organizations may submit more than one application, provided that each application is scientifically distinct.</p>

<p>The NIH will not accept duplicate or highly overlapping applications under review at the same time, per <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=82415">NIH Grants Policy Statement Section 2.3.7.4 Submission of Resubmission Application</a>.&nbsp;This means that the NIH will not accept:</p>

<ul>
	<li>A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.</li>
	<li>A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.</li>
	<li>An application that has substantial overlap with another application pending appeal of initial peer review (see <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=82423">NIH Grants Policy Statement 2.3.9.4 Similar, Essentially Identical, or Identical Applications</a>).</li>
</ul>
		</div>

	
		
	
	
		
		

		<div data-element-id="220663" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="EI" data-element-type="TEXT">
			 
		</div>

	
		
	
	
		
		

		<div data-element-id="220664" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220664' tabindex='-1' aria-hidden='true'></a><a name="_Section IV. Application and Submission Information"></a><h2>Section IV. Application and Submission Information</h2>
		</div>

	
		
	
	
		
		

		<div data-element-id="220665" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220665' tabindex='-1' aria-hidden='true'></a><h4>1. Requesting an Application Package</h4><p>The application forms package specific to this opportunity must be accessed through ASSIST, Grants.gov Workspace or an institutional system-to-system solution. Links to apply using ASSIST or Grants.gov Workspace are available in Part 1 of this NOFO. See your administrative office for instructions if you plan to use an institutional system-to-system solution.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220666" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220666' tabindex='-1' aria-hidden='true'></a><h4>2. Content and Form of Application Submission</h4><p>It is critical that applicants follow the instructions in the Research (R) Instructions in the&nbsp;<a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=82400">How to Apply - Application Guide</a>&nbsp;except where instructed in this notice of funding opportunity to do otherwise. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220667" data-element-has-label="false" data-element-required="false" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220667' tabindex='-1' aria-hidden='true'></a><h4>Letter of Intent</h4><p>Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.</p><p>By the date listed in <a href="#_Part_1._Overview">Part 1. Overview Information</a>, prospective applicants are asked to submit a letter of intent that includes the following information:</p><ul><li>Descriptive title of proposed activity</li><li>Name(s), address(es), and telephone number(s) of the PD(s)/PI(s)</li><li>Names of other key personnel</li><li>Participating institution(s)</li><li>Number and title of this funding opportunity</li></ul><p>The letter of intent should be sent to: <a href="/cdn-cgi/l/email-protection#a4eaede0e5e8c1d0d0c1d6cbc2edcad0c1cad0e4c9c5cdc88acacdcc8ac3cbd2"><span class="__cf_email__" data-cfemail="511f1815101d34252534233e37183f25343f25113c30383d7f3f38397f363e27">[email&#160;protected]</span></a></p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220668" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220668' tabindex='-1' aria-hidden='true'></a><h4>Page Limitations</h4><p>All page limitations described in the <a href="https://grants.nih.gov/grants/how-to-apply-application-guide.html">How to Apply- Application Guide</a> and the <a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=61134">Table of Page Limits</a> must be followed.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220669" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="ASI" data-element-type="TEXT">
			 
		</div>

	
		
	
	
		
		
		  		<div class="heading4" tabindex="0" data-element-id="220670" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
						<a id='_bookmark220670' tabindex='-1' aria-hidden='true'></a>Instructions for Application Submission 					
				</div>

		<div data-element-id="220670" data-element-has-label="true" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <p>The following section supplements the instructions found in the <a href="https://grants.nih.gov/grants/how-to-apply-application-guide.html">How to Apply- Application Guide</a> and should be used for preparing an application to this NOFO.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220671" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220671' tabindex='-1' aria-hidden='true'></a><h4>SF424(R&amp;R) Cover</h4><p>All instructions in the How to Apply- Application Guide must be followed.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220673" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220673' tabindex='-1' aria-hidden='true'></a><h4>SF424(R&amp;R) Project/Performance Site Locations</h4><p>All instructions in the How to Apply-Application Guide must be followed.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220674" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="ASI" data-element-type="TEXT">
			 
		</div>

	
		
	
	
		
		

		<div data-element-id="220675" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220675' tabindex='-1' aria-hidden='true'></a><h4>SF424(R&amp;R) Other Project Information</h4><p>All instructions in the How to Apply-Application Guide must be followed.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220676" data-element-has-label="false" data-element-required="false" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220676' tabindex='-1' aria-hidden='true'></a><p data-suggestion-start-before="insertion:ecbbfdb92b8e250a8775b6c812c0a383f:MONTOYAI">Other Attachments:</p><p></p><p><strong>Target Product Profile (Optional):</strong></p><p>Applicants may include a target product profile for therapeutic candidates. This may not exceed one page in length.</p><p><strong>Interactions with FDA (Optional):</strong></p><p>Applications may include a summary of interactions with FDA, which may not to exceed two pages in length.</p><p>Applications exceeding the above page limitations or including other information in these attachments, will be withdrawn without review.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220677" data-element-has-label="false" data-element-required="false" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220677' tabindex='-1' aria-hidden='true'></a><p><strong></strong> </p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220678" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220678' tabindex='-1' aria-hidden='true'></a><h4>SF424(R&amp;R) Senior/Key Person Profile</h4><p>All instructions in the How to Apply- Application Guide must be followed.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220680" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220680' tabindex='-1' aria-hidden='true'></a><h4>R&amp;R Budget</h4><p>All instructions in the How to Apply- Application Guide must be followed.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220682" data-element-has-label="false" data-element-required="false" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220682' tabindex='-1' aria-hidden='true'></a><p> </p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220683" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220683' tabindex='-1' aria-hidden='true'></a><h4>R&amp;R Subaward Budget</h4><p>All instructions in the How to Apply-Application Guide must be followed.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220684" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="ASI" data-element-type="TEXT">
			 
		</div>

	
		
	
	
		
		

		<div data-element-id="220685" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220685' tabindex='-1' aria-hidden='true'></a><h4>PHS 398 Cover Page Supplement</h4><p>All instructions in the How to Apply- Application Guide must be followed.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220687" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220687' tabindex='-1' aria-hidden='true'></a><h4>PHS 398 Research Plan</h4><p>All instructions in the How to Apply- Application Guide must be followed, with the following additional instructions:</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220688" data-element-has-label="false" data-element-required="false" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220688' tabindex='-1' aria-hidden='true'></a><p style="margin-left:0in;"><strong>Research Strategy</strong>:</p><p style="margin-left:0in;">Without duplicating the information provided in Section 2.7 Study Timeline from PHS Human Subjects and Clinical Trials Information Form, include a study timeline that relates to the anticipated completion of Aims and/or milestones.&nbsp;</p><p style="margin-left:0in;">Applications must provide a decision tree for the compound testing, with appropriate go/no-go decision points. They must also provide the entry and exit points of the proposed compound in the FDA's medications development continuum, if applicable.</p><p style="margin-left:0in;"><strong>Milestones and UG3/UH3 Transition</strong>: Applicants must plan and submit the application for both a UG3 and a UH3 phases. The section describing the research to be conducted under the UG3 must include a description of an entry point and the milestone(s) that will be reached at the end of this phase.</p><p style="margin-left:0in;">To successfully transition to the UH3 phase, the project must reach the milestones outlined in the application. The application must provide quantifiable metrics to determine success of the UG3. Additional milestone(s) may be negotiated before or after funding decisions have been made.</p><p style="margin-left:0in;">All clinical trial applications must include methods to evaluate subjects' compliance with the study medications.</p><p style="margin-left:0in;">If applicable, investigators must include male and female samples and data analysis to evaluate potential sex/gender differences. When samples or analysis are not proposed, scientific justification must be provided.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220689" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220689' tabindex='-1' aria-hidden='true'></a><p><strong>Resource Sharing Plan:&nbsp;</strong>Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the How to Apply- Application Guide.&nbsp;</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220690" data-element-has-label="false" data-element-required="false" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220690' tabindex='-1' aria-hidden='true'></a><p></p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220691" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220691' tabindex='-1' aria-hidden='true'></a><p><strong>Other Plan(s):&nbsp;</strong></p><p>All instructions in the How to Apply-Application Guide must be followed, with the following additional instructions:</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220692" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220692' tabindex='-1' aria-hidden='true'></a><ul><li>All applicants planning research (funded or conducted in whole or in part by NIH) that results in the generation of scientific data are required to comply with the instructions for the Data Management and Sharing Plan. All applications, regardless of the amount of direct costs requested for any one year, must address a Data Management and Sharing Plan.</li></ul><p></p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220693" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220693' tabindex='-1' aria-hidden='true'></a><p><strong>Appendix: </strong>Only limited Appendix materials are allowed. Follow all instructions for the Appendix as described in the How to Apply- Application Guide.</p><ul><li>No publications or other material, with the exception of blank questionnaires or blank surveys, may be included in the Appendix.</li></ul>
		</div>

	
		
	
	
		
		

		<div data-element-id="220694" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="ASI" data-element-type="TEXT">
			 
		</div>

	
		
	
	
		
		

		<div data-element-id="220695" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220695' tabindex='-1' aria-hidden='true'></a><h4>PHS Human Subjects and Clinical Trials Information</h4><p>When involving human subjects research, clinical research, and/or NIH-definedclinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the How to Apply- Application Guide, with the following additional instructions:</p><p>If you answered &#147;Yes&#148; to the question &#147;Are Human Subjects Involved?&#148; on the R&amp;R Other Project Information form, you must include at least one human subjects study record using the <strong>Study Record: PHS Human Subjects and Clinical Trials Information </strong>form or <strong>Delayed Onset Study</strong> record.</p><p><strong>Study Record: PHS Human Subjects and Clinical Trials Information</strong></p><p>All instructions in the How to Apply- Application Guide must be followed.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220696" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="ASI" data-element-type="TEXT">
			 
		</div>

	
		
	
	
		
		

		<div data-element-id="220697" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220697' tabindex='-1' aria-hidden='true'></a><p><strong>Delayed Onset Study</strong></p><p>Note: <a href="https://grants.nih.gov/grants/glossary.htm#DelayedOnsetStudy">Delayed onset</a> does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the How to Apply-Application Guide must be followed.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220698" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="ASI" data-element-type="TEXT">
			 
		</div>

	
		
	
	
		
		

		<div data-element-id="220699" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220699' tabindex='-1' aria-hidden='true'></a><h4>PHS Assignment Request Form</h4><p>All instructions in the How to Apply-Application Guide must be followed.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220701" data-element-has-label="false" data-element-required="false" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220701' tabindex='-1' aria-hidden='true'></a><h4>Foreign Organizations</h4><p>Foreign (non-U.S.) institutions must follow policies described in the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11137">NIH Grants Policy Statement</a>, and procedures for foreign institutions described throughout the How to Apply-Application Guide.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220702" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220702' tabindex='-1' aria-hidden='true'></a><h4>3. Unique Entity Identifier and System for Award Management (SAM)</h4><p>See Part 2. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220703" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220703' tabindex='-1' aria-hidden='true'></a><h4>4. Submission Dates and Times</h4><p><a href="#_Part_1._Overview">Part I. Overview Information</a> contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or <a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=82380">Federal holiday</a>, the application deadline is automatically extended to the next business day.</p><p>Organizations must submit applications to <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11128">Grants.gov</a> (the online portal to find and apply for grants across all Federal agencies). Applicants must then complete the submission process by tracking the status of the application in the <a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=11123">eRA Commons</a>, NIH&#146;s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. &nbsp;If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=82423">NIH Grants Policy Statement Section 2.3.9.2 Electronically Submitted Applications</a>.</p><p><strong>Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.</strong></p><p>Information on the submission process and a definition of on-time submission are provided in the How to Apply- Application Guide.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220704" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220704' tabindex='-1' aria-hidden='true'></a><h4>5. Intergovernmental Review (E.O. 12372)</h4><p>This initiative is not subject to <a href="https://grants.nih.gov/grants/policy/nihgps/html5/section_10/10.10.1_executive_orders.htm">intergovernmental review.</a></p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220705" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="ASI" data-element-type="TEXT">
			 
		</div>

	
		
	
	
		
		

		<div data-element-id="220706" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220706' tabindex='-1' aria-hidden='true'></a><h4>6. Funding Restrictions</h4><p>All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11120">NIH Grants Policy Statement</a>.</p><p>Pre-award costs are allowable only as described in the&nbsp;<a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11143">NIH Grants Policy Statement Section 7.9.1 Selected Items of Cost.</a></p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220707" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="ASI" data-element-type="TEXT">
			 
		</div>

	
		
	
	
		
		
		  		<div class="heading4" tabindex="0" data-element-id="220708" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
						<a id='_bookmark220708' tabindex='-1' aria-hidden='true'></a>7. Other Submission Requirements and Information 					
				</div>

		<div data-element-id="220708" data-element-has-label="true" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <p>Applications must be submitted electronically following the instructions described in the <a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=82400">How to Apply - Application Guide</a>. Paper applications will not be accepted.</p><p>Applicants must complete all required registrations before the application due date. <a href="#_Section_III._Eligibility">Section III. Eligibility Information</a> contains information about registration.</p><p>For assistance with your electronic application or for more information on the electronic submission process, visit <a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=82400"><u>How to Apply &ndash; Application Guide</u></a>. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the <a href="https://grants.nih.gov/grants/how-to-apply-application-guide/due-dates-and-submission-policies/dealing-with-system-issues.htm">Dealing with System Issues</a> guidance. For assistance with application submission, contact the Application Submission Contacts in <a href="#_Section_VII._Agency">Section VII</a>.</p><p style="margin-left:25px;"><strong>Important reminders:</strong></p><p style="margin-left:25px;">All PD(s)/PI(s) must include their eRA Commons ID in the Credential field of the Senior/Key Person Profile form<strong>. </strong>Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH. See Section III of this NOFO for information on registration requirements.</p><p style="margin-left:25px;">The applicant organization must ensure that the unique entity identifier provided on the application is the same identifier used in the organization&#146;s profile in the eRA Commons and for the System for Award Management. Additional information may be found in the <a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=82400">How to Apply - Application Guide</a>.</p><p style="margin-left:25px;">See <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11146">more tips</a> for avoiding common errors.</p> 
		</div>

	
		
	
	
		
		

		<div data-element-id="220709" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220709' tabindex='-1' aria-hidden='true'></a><p>Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by NIDA, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220710" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="ASI" data-element-type="TEXT">
			 
		</div>

	
		
	
	
		
		

		<div data-element-id="220711" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="ASI" data-element-type="TEXT">
			 
		</div>

	
		
	
	
		
		
		  		<div class="heading4" tabindex="0" data-element-id="220712" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
						<a id='_bookmark220712' tabindex='-1' aria-hidden='true'></a>Mandatory Disclosure 					
				</div>

		<div data-element-id="220712" data-element-has-label="true" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <p>Recipients or subrecipients must submit any information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. See Mandatory Disclosures,&nbsp;<a href="https://www.ecfr.gov/current/title-2/subtitle-A/chapter-II/part-200/subpart-B/section-200.113">2 CFR 200.113</a> &nbsp;and <a href="https://grants.nih.gov/grants/policy/nihgps/html5/section_4/4.1.35_mandatory_disclosures.htm">NIH Grants Policy Statement Section 4.1.35</a>.</p><p>Send written disclosures to the NIH Chief Grants Management Officer listed on the Notice of Award for the IC that funded the award and to the&nbsp;<a href="https://oig.hhs.gov/compliance/self-disclosure-info/hhs-oig-grant-self-disclosure-program/">HHS Office of Inspector Grant Self Disclosure Program</a> at <a href="/cdn-cgi/l/email-protection#462134272832222f35252a29353334233506292f21682e2e3568212930"><span class="__cf_email__" data-cfemail="e78095868993838e94848b889492958294a7888e80c98f8f94c9808891">[email&#160;protected]</span></a>.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220713" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ASI" data-element-type="TEXT">
			 <a id='_bookmark220713' tabindex='-1' aria-hidden='true'></a><h4>Post Submission Materials</h4><p>Applicants are required to follow the instructions for post-submission materials, as described in <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=82299">the policy</a></p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220714" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="ASI" data-element-type="TEXT">
			 
		</div>

	
		
	
	
		
		

		<div data-element-id="220715" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <a id='_bookmark220715' tabindex='-1' aria-hidden='true'></a><a name="_Section V. Application Review Information"></a><h2>Section V. Application Review Information</h2>
		</div>

	
		
	
	
		
		

		<div data-element-id="220716" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <a id='_bookmark220716' tabindex='-1' aria-hidden='true'></a><h4>1. Criteria</h4><p>Only the review criteria described below will be considered in the review process. Applications submitted to the NIH in support of the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11149">NIH mission</a> are evaluated for scientific and technical merit through the NIH peer review system.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220717" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="ARI" data-element-type="TEXT">
			 
		</div>

	
		
	
	
		
		
		  		<div class="heading4" tabindex="0" data-element-id="220718" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
						<a id='_bookmark220718' tabindex='-1' aria-hidden='true'></a> Overall Impact 					
				</div>

		<div data-element-id="220718" data-element-has-label="true" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <p>Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following scored review criteria and additional review criteria (as applicable for the project proposed).&nbsp; An application does not need to be strong in all categories to be judged likely to have a major scientific impact. </p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220720" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <a id='_bookmark220720' tabindex='-1' aria-hidden='true'></a><h4>Review Criteria</h4><p>Reviewers will consider Factors 1, 2 and 3 in the determination of scientific merit, and in providing an overall impact score. In addition, Factors 1 and 2 will each receive a separate factor score.&nbsp;</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220721" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <a id='_bookmark220721' tabindex='-1' aria-hidden='true'></a><h4>Factor 1: Importance of the Research</h4><p><i><strong>Significance</strong></i></p><ul><li>Evaluate the importance of the proposed research in the context of current scientific challenges and opportunities, either for advancing knowledge within the field, or more broadly. Assess whether the application addresses an important gap in knowledge in the field, would solve a critical problem, or create a valuable conceptual or technical advance.</li><li>Evaluate the rationale for undertaking the study, the rigor of the scientific background for the work (e.g. prior literature and/or preliminary data) and whether the scientific background justifies the proposed study.</li></ul><p><i><strong>Innovation</strong></i></p><ul><li>Evaluate the extent to which innovation influences the importance of undertaking the proposed research. Note that while technical or conceptual innovation can influence the importance of the proposed research, a project that is not applying novel concepts or approaches may be of critical importance for the field.</li><li>Evaluate whether the proposed work applies novel concepts, methods or technologies, or uses existing concepts, methods, technologies in novel ways, to enhance the overall impact of the project.</li></ul>
		</div>

	
		
	
	
		
		

		<div data-element-id="220722" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="ARI" data-element-type="TEXT">
			 
		</div>

	
		
	
	
		
		

		<div data-element-id="220723" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <a id='_bookmark220723' tabindex='-1' aria-hidden='true'></a><h4>Factor 2. Rigor and Feasibility</h4><p><i><strong>Approach</strong></i></p><ul><li>Evaluate the scientific quality of the proposed work. Evaluate the likelihood that compelling, reproducible findings will result (rigor) and assess whether the proposed studies can be done well and within the timeframes proposed (feasibility).</li></ul><p><i><strong>Rigor:</strong></i></p><ul><li>Evaluate the potential to produce unbiased, reproducible, robust data.</li><li>Evaluate the rigor of experimental design and whether appropriate controls are in place.</li><li>Evaluate whether the sample size is sufficient and well-justified.</li><li>Assess the quality of the plans for analysis, interpretation, and reporting of results.</li><li>Evaluate whether the investigators presented adequate plans to address relevant biological variables, such as sex or age, in the design, analysis, and reporting.</li><li>For applications involving human subjects or vertebrate animals, also evaluate:<ul><li>the rigor of the intervention or study manipulation (if applicable to the study design).</li><li>whether outcome variables are justified.</li><li>whether the results will be generalizable or, in the case of a rare disease/special group, relevant to the particular subgroup.</li><li>whether the sample is appropriate and sufficiently diverse to address the proposed question(s).</li></ul></li><li>For applications involving human subjects, including clinical trials, assess the adequacy of inclusion plans as appropriate for the scientific goals of the research. Considerations of appropriateness may include disease/condition/behavior incidence, prevalence, or population burden, population representation, and/or current state of the science.</li></ul><p><i><strong>Feasibility:</strong></i></p><ul><li>Evaluate whether the proposed approach is sound and achievable, including plans to address problems or new challenges that emerge in the work. For proposed studies in which feasibility may be less certain, evaluate whether the uncertainty is balanced by the potential for major advances.</li><li>For applications involving human subjects, including clinical trials, evaluate the adequacy and feasibility of the plan to recruit and retain an appropriately diverse population of participants. Additionally, evaluate the likelihood of successfully achieving the proposed enrollment based on age, racial, ethnic, and sex or gender categories.</li><li>For clinical trial applications, evaluate whether the study timeline and milestones are feasible.</li></ul>
		</div>

	
		
	
	
		
		

		<div data-element-id="220724" data-element-has-label="false" data-element-required="false" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <a id='_bookmark220724' tabindex='-1' aria-hidden='true'></a><p><i><strong>Specific for this NOFO:</strong></i></p><ul><li>Evaluate whether UG3 Phase includes a description of an FDA-defined entry point of the compound.</li><li>Evaluate whether the application includes the milestone(s) in the FDA approval pathway that will be reached at the end of the UG3 Phase.</li><li>Evaluate whether the application provides quantifiable metrics that support the successful transition from the UG3 Phase to the UH3 Phase.</li></ul>
		</div>

	
		
	
	
		
		

		<div data-element-id="220725" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <a id='_bookmark220725' tabindex='-1' aria-hidden='true'></a><h4>Factor 3. Expertise and Resources</h4><p><i><strong>Investigator(s)</strong></i></p><ul><li>Evaluate whether the investigator(s) have demonstrated background, training, and expertise, as appropriate for their career stage, to conduct the proposed work. For Multiple Principal Investigator (MPI) applications, assess the quality of the leadership plan to facilitate coordination and collaboration.</li></ul><p><i><strong>Environment</strong></i></p><ul><li>Evaluate whether the institutional resources are appropriate to ensure the successful execution of the proposed work.</li></ul>
		</div>

	
		
	
	
		
		

		<div data-element-id="220726" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="ARI" data-element-type="TEXT">
			 
		</div>

	
		
	
	
		
		
		  		<div class="heading4" tabindex="0" data-element-id="220727" data-element-required="false" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
						<a id='_bookmark220727' tabindex='-1' aria-hidden='true'></a>Additional Review Criteria  					
				</div>

		<div data-element-id="220727" data-element-has-label="true" data-element-required="false" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <p></p><p>As applicable for the project proposed, reviewers will consider the following additional items while determining scientific and technical merit, but will not give criterion scores for these items, and should consider them in providing an overall impact score.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220729" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <a id='_bookmark220729' tabindex='-1' aria-hidden='true'></a><h4 style="margin-left:25px;">Protections for Human Subjects</h4><p style="margin-left:25px;">For research that involves human subjects but does not involve one of the categories of research that are exempt under 45 CFR Part 46, evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.</p><p style="margin-left:25px;">For research that involves human subjects and meets the criteria for one or more of the categories of research that are exempt under 45 CFR Part 46, evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the&nbsp;<a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=11175">Guidelines for the Review of Human Subjects</a>.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220730" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <a id='_bookmark220730' tabindex='-1' aria-hidden='true'></a><p class="heading4" style="margin-left: 25px;">Vertebrate Animals</p>

<p class="Normal" style="margin-left: 25px;">When the proposed research includes Vertebrate Animals, evaluate the involvement of live vertebrate animals according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. For additional information on review of the Vertebrate Animals section, please refer to the&nbsp;<a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11150">Worksheet for Review of the Vertebrate Animals Section</a>.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220731" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <a id='_bookmark220731' tabindex='-1' aria-hidden='true'></a><p class="heading4" style="margin-left: 25px;">Biohazards</p>

<p class="Normal" style="margin-left: 25px;">When the proposed research includes Biohazards, evaluate whether specific materials or procedures that will be used are significantly hazardous to research personnel and/or the environment, and whether adequate protection is proposed.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220732" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <a id='_bookmark220732' tabindex='-1' aria-hidden='true'></a><p class="heading4" style="margin-left: 25px;">Resubmissions</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220733" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <a id='_bookmark220733' tabindex='-1' aria-hidden='true'></a><p style="margin-left:25px;">As applicable, evaluate the application as now presented.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220734" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <a id='_bookmark220734' tabindex='-1' aria-hidden='true'></a><p class="heading4" style="margin-left: 25px;">Renewals</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220735" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <a id='_bookmark220735' tabindex='-1' aria-hidden='true'></a><p style="margin-left:25px;">Not Applicable</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220736" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <a id='_bookmark220736' tabindex='-1' aria-hidden='true'></a><p class="heading4" style="margin-left: 25px;">Revisions</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220737" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <a id='_bookmark220737' tabindex='-1' aria-hidden='true'></a><p style="margin-left:25px;">As applicable, evaluate the appropriateness of the proposed expansion of the scope of the project. If the Revision application relates to a specific line of investigation presented in the original application that was not recommended for approval by the committee, then the committee will consider whether the responses to comments from the previous scientific review group are adequate and whether substantial changes are clearly evident.</p>
		</div>

	
		
	
	
		
		
		  		<div class="heading4" tabindex="0" data-element-id="220738" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
						<a id='_bookmark220738' tabindex='-1' aria-hidden='true'></a>Additional Review Considerations 					
				</div>

		<div data-element-id="220738" data-element-has-label="true" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <p>As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220739" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="ARI" data-element-type="TEXT">
			 
		</div>

	
		
	
	
		
		

		<div data-element-id="220740" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <a id='_bookmark220740' tabindex='-1' aria-hidden='true'></a><p class="heading4" style="margin-left: 25px;">Authentication of Key Biological and/or Chemical Resources:</p>

<p class="Normal" style="margin-left: 25px;">For projects involving key biological and/or chemical resources, evaluate the brief plans proposed for identifying and ensuring the validity of those resources.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220741" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <a id='_bookmark220741' tabindex='-1' aria-hidden='true'></a><h4 style="margin-left:25px;">Budget and Period of Support</h4><p style="margin-left:25px;">Evaluate whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220742" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <a id='_bookmark220742' tabindex='-1' aria-hidden='true'></a><h4>2. Review and Selection Process</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220743" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <a id='_bookmark220743' tabindex='-1' aria-hidden='true'></a><p>Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by NIDA, in accordance with <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11154">NIH peer review policy and procedures</a>, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220744" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <a id='_bookmark220744' tabindex='-1' aria-hidden='true'></a><p>As part of the scientific peer review, all applications will receive a written critique.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220745" data-element-has-label="false" data-element-required="false" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <a id='_bookmark220745' tabindex='-1' aria-hidden='true'></a><p>Applications may undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.</p>
		</div>

	
		
		
		

		<div data-element-id="220746" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="ARI" data-element-type="CHECKBOX">
			 
		</div>

	
		
	
	
		
		

		<div data-element-id="220747" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <a id='_bookmark220747' tabindex='-1' aria-hidden='true'></a><p>Applications will be assigned on the basis of established PHS referral guidelines to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this NOFO. Following initial peer review, recommended applications will receive a second level of review by the appropriate national Advisory Council or Board. The following will be considered in making funding decisions, consistent with applicable law.</p><ul><li>Scientific and technical merit of the proposed project as determined by scientific peer review.</li><li>Availability of funds.</li><li>Relevance of the proposed project to program priorities.</li></ul><p>Please note that reviewers will not consider race, ethnicity, age, or gender (including gender identity, sexual orientation or gender status) of a researcher, award participant, or trainee, even in part, in providing critiques, scores, or funding recommendations. NIH will not consider such factors in making its funding decisions.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220748" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <a id='_bookmark220748' tabindex='-1' aria-hidden='true'></a><p>If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in the&nbsp;<a href="//grants.nih.gov/grants/guide/url_redirect.php?id=82418">NIH Grants Policy Statement Section 2.5.1. Just-in-Time Procedures</a>. This request is not a Notice of Award nor should it be construed to be an indicator of possible funding.</p><p>Prior to making an award, NIH reviews an applicant&#146;s federal award history in SAM.gov to ensure sound business practices.&nbsp;An applicant can review and comment on any information in the Responsibility/Qualification records available in SAM.gov.&nbsp; NIH will consider any comments by the applicant in the Responsibility/Qualification records in SAM.gov to ascertain the applicant&#146;s integrity, business ethics, and performance record of managing Federal awards per 2 CFR Part 200.206 &#147;Federal awarding agency review of risk posed by applicants.&#148;&nbsp; This provision will apply to all NIH grants and cooperative agreements except fellowships.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220749" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="ARI" data-element-type="TEXT">
			 <a id='_bookmark220749' tabindex='-1' aria-hidden='true'></a><h4>3. Anticipated Announcement and Award Dates</h4><p>After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the&nbsp;<a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=11123">eRA Commons</a>.&nbsp;Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.</p><p>Information regarding the disposition of applications is available in the&nbsp;<a href="//grants.nih.gov/grants/guide/url_redirect.php?id=82416">NIH Grants Policy Statement Section 2.4.4 Disposition of Applications</a>.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220750" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="AAI" data-element-type="TEXT">
			 <a id='_bookmark220750' tabindex='-1' aria-hidden='true'></a><a name="_Section VI. Award Administration Information"></a><h2>Section VI. Award Administration Information</h2>
		</div>

	
		
	
	
		
		

		<div data-element-id="220751" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="AAI" data-element-type="TEXT">
			 <a id='_bookmark220751' tabindex='-1' aria-hidden='true'></a><h4>1. Award Notices</h4><p>A Notice of Award (NoA) is the official authorizing document notifying the applicant that an award has been made and that funds may be requested from the designated HHS payment system or office. The NoA is signed by the Grants Management Officer and emailed to the recipient&#146;s business official.</p><p>In accepting the award, the recipient agrees that any activities under the award are subject to all provisions currently in effect or implemented during the period of the award, other Department regulations and policies in effect at the time of the award, and applicable statutory provisions.</p><p>Recipients must comply with any funding restrictions described in&nbsp;<a href="#_6._Funding_Restrictions">Section IV.6. Funding Restrictions</a>. Any pre-award costs incurred before receipt of the NoA are at the applicant's own risk. For more information on the Notice of Award, please refer to the&nbsp;<a href="https://grants.nih.gov/grants/policy/nihgps/HTML5/section_5/5_the_notice_of_award.htm">NIH Grants Policy Statement Section 5. The Notice of Award</a> and NIH Grants &amp; Funding website, see <a href="https://grants.nih.gov/grants/pre-award-process.htm#award">Award Process.</a></p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220752" data-element-has-label="false" data-element-required="false" data-element-has-value="true" data-section-code="AAI" data-element-type="TEXT">
			 <a id='_bookmark220752' tabindex='-1' aria-hidden='true'></a><p>Individual awards are based on the application submitted to, and as approved by, the NIH and are subject to the IC-specific terms and conditions identified in the NoA.</p>

<p>ClinicalTrials.gov: If an award provides for one or more clinical trials. By law (Title VIII, Section 801 of Public Law 110-85), the "responsible party" must register and submit results information for certain &#147;applicable clinical trials&#148; on the ClinicalTrials.gov Protocol Registration and Results System Information Website (<a href="https://register.clinicaltrials.gov/">https://register.clinicaltrials.gov</a>). NIH expects registration and results reporting of all trials whether required under the law or not. For more information, see <a href="https://grants.nih.gov/policy/clinical-trials/reporting/index.htm">https://grants.nih.gov/policy/clinical-trials/reporting/index.htm</a></p>

<p>Institutional Review Board or Independent Ethics Committee Approval: Recipient institutions must ensure that all protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the recipient must provide NIH copies of documents related to all major changes in the status of ongoing protocols.</p>

<p>Data and Safety Monitoring Requirements: The NIH policy for data and safety monitoring requires oversight and monitoring of all NIH-conducted or -supported human biomedical and behavioral intervention studies (clinical trials) to ensure the safety of participants and the validity and integrity of the data. Further information concerning these requirements is found at http://grants.nih.gov/grants/policy/hs/data_safety.htm and in the application instructions (SF424 (R&amp;R) and PHS 398).</p>

<p>Investigational New Drug or Investigational Device Exemption Requirements: Consistent with federal regulations, clinical research projects involving the use of investigational therapeutics, vaccines, or other medical interventions (including licensed products and devices for a purpose other than that for which they were licensed) in humans under a research protocol must be performed under a Food and Drug Administration (FDA) investigational new drug (IND) or investigational device exemption (IDE).</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220753" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="AAI" data-element-type="TEXT">
			 <a id='_bookmark220753' tabindex='-1' aria-hidden='true'></a><h4>2. Administrative and National Policy Requirements</h4><p>The following Federal wide and HHS-specific policy requirements apply to awards funded through NIH:</p><ul><li>The rules listed at <a href="https://www.ecfr.gov/current/title-2/subtitle-A/chapter-II/part-200">2 CFR Part 200</a>, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards.</li><li>All NIH grant and cooperative agreement awards include the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11120">NIH Grants Policy Statement</a> as part of the terms and conditions in the Notice of Award (NoA). The NoA includes the requirements of this NOFO. For these terms of award, see the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11120">NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: General</a> and <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11159">Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Recipients, and Activities</a>.</li><li>If a recipient receives an award, the recipient must follow all applicable nondiscrimination laws. The recipient agrees to this when registering in SAM.gov. The recipient must also submit an Assurance of Compliance (<a href="https://www.hhs.gov/sites/default/files/form-hhs690.pdf">HHS-690</a>). To learn more, see the <a href="https://www.hhs.gov/civil-rights/for-providers/laws-regulations-guidance/laws/index.html">Laws and Regulations Enforced by the&nbsp;HHS Office for Civil Rights website</a>.<ul><li>HHS recognizes that NIH research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator&#146;s scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research. For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this NOFO.</li></ul></li></ul><p>All federal statutes and regulations relevant to federal financial assistance, including those highlighted in&nbsp;<a href="https://grants.nih.gov/grants/policy/nihgps/HTML5/section_4/4_public_policy_requirements__objectives_and_other_appropriation_mandates.htm">NIH Grants Policy Statement Section 4 Public Policy Requirements, Objectives and Other Appropriation Mandates.</a></p><p>Recipients are responsible for ensuring that their activities comply with all applicable federal regulations.&nbsp; NIH may terminate awards under certain circumstances.&nbsp; See&nbsp;<a href="https://www.ecfr.gov/current/title-2/subtitle-A/chapter-II/part-200/subpart-D/subject-group-ECFR86b76dde0e1e9dc/section-200.340">2 CFR Part 200.340 Termination</a> and&nbsp;<a href="https://grants.nih.gov/grants/policy/nihgps/html5/section_8/8.5.2_remedies_for_noncompliance_or_enforcement_actions-_suspension__termination__and_withholding_of_support.htm">NIH Grants Policy Statement Section 8.5.2 Remedies for Noncompliance or Enforcement Actions: Suspension, Termination, and Withholding of Support</a>.&nbsp;</p><p>Successful recipients under this NOFO agree that:</p><p>Where the award funding involves implementing, acquiring, or upgrading health IT for activities by any funded entity, recipients and subrecipient(s) are required to: Use health IT that meets standards and implementation specifications adopted in 45 CFR part 170, Subpart B, if such standards and implementation specifications can support the activity.&nbsp; Visit <a href="https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-D/part-170/subpart-B">https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-D/part-170/subpart-B</a> to learn more.</p><p>Where the award funding involves implementing, acquiring, or upgrading health IT for activities by eligible clinicians in ambulatory settings, or hospitals, eligible under Sections 4101, 4102, and 4201 of the HITECH Act, use health IT certified under the ONC Health IT Certification Program if certified technology can support the activity. Visit <a href="https://www.healthit.gov/topic/certification-ehrs/certification-health-it">https://www.healthit.gov/topic/certification-ehrs/certification-health-it</a> to learn more.</p><p>Pursuant to the Cybersecurity Act of 2015, Div. N, &#x00a7; 405, Pub. Law 114-113, 6 USC &#x00a7; 1533(d), the HHS Secretary has established a common set of voluntary, consensus-based, and industry-led guidelines, best practices, methodologies, procedures, and processes.</p><p>Successful recipients under this NOFO agree that:</p><p>When recipients, subrecipients, or third-party entities have:</p><p>&nbsp; &nbsp; &nbsp; &nbsp; 1) ongoing and consistent access to HHS owned or operated information or operational technology systems; and&nbsp;</p><p>&nbsp; &nbsp; &nbsp; &nbsp; 2) receive, maintain, transmit, store, access, exchange, process, or utilize personal identifiable information (PII) or personal health information (PHI) obtained from the awarding HHS agency for the purposes of executing the award.</p><p>Recipients shall develop plans and procedures, modeled after the <a href="https://www.nist.gov/cyberframework">NIST Cybersecurity framework</a>, to protect HHS systems and data. Please refer to <a href="https://grants.nih.gov/grants/post-award-monitoring-and-reporting.htm">NIH Post-Award Monitoring and Reporting</a> for additional information.&nbsp;</p>
		</div>

	
		
	
	
		
		
		  		<div class="heading4" tabindex="0" data-element-id="220754" data-element-required="true" data-element-has-value="true" data-section-code="AAI" data-element-type="TEXT">
						<a id='_bookmark220754' tabindex='-1' aria-hidden='true'></a>Cooperative Agreement Terms and Conditions of Award  					
				</div>

		<div data-element-id="220754" data-element-has-label="true" data-element-required="true" data-element-has-value="true" data-section-code="AAI" data-element-type="TEXT">
			 <p>The following special terms of award are in addition to, and not in lieu of, otherwise applicable U.S. Office of Management and Budget (OMB) administrative guidelines, U.S. Department of Health and Human Services (DHHS) grant administration regulations at 2 CFR Part 200, and other HHS, PHS, and NIH grant administration policies.</p><p>The administrative and funding instrument used for this program will be the cooperative agreement, an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH programmatic involvement with the recipients&nbsp;is anticipated during the performance of the activities. Under the cooperative agreement, the NIH purpose is to support and stimulate the recipients' activities by involvement in and otherwise working jointly with the award recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility resides with the recipients&nbsp;for the project as a whole, although specific tasks and activities may be shared among the recipients&nbsp;and the NIH as defined below.</p><p><strong>The PD(s)/PI(s) will have the primary responsibility for:</strong></p><p>All aspects of their study, including any modification of study design, conduct of the study, quality control, data analysis and interpretation, preparation of publications, dissemination of data, tools, and technologies, and collaboration with other investigators.</p><p>The recipient&nbsp;agrees to accept close coordination, cooperation, and participation of NIH staff in those aspects of scientific and technical management of the study including those outlined under "NIH Responsibilities".</p><p>Award recipients&nbsp;will participate in annual meetings of the recipients&nbsp;and will support any committees, task forces, and advisory panels as needed.</p><p>Upon implementation of the protocol, each field center, whether a single institution or a consortium of institutions, will follow the procedures required by the protocol regarding study conduct and monitoring, patient management, and data collection.</p><p>Support or other involvement of industry or any other third party in the study--e.g., participation by the third party; involvement of project resources or citing the name of the project or the NIH support; or special access to project results, data, findings, or resources--may be advantageous and appropriate. However, except for licensing of patents or copyrights, support or involvement of any third party will occur with the concurrence by NIH Program Officer to ensure objectivity of research.</p><p>Award recipients will own the rights in any tangible work products created under the terms of the cooperative agreement. Work products may include such things as research reports, papers, research, findings, training curricula, data sets, books, patient tools, and other materials. All such products shall be made accessible to the public. Recipients(s) will retain custody of and have primary rights to the data and software developed under these awards, subject to Government policies subject to Government policies regarding rights of access DHHS, PHS, and NIH policies.</p><p><strong>NIH staff have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below:</strong></p><p>The NIH Project Scientist will have access to the data and work with the PD(s)/PI(s) to ensure the objectives of the program are being met. The primary responsibility for the program resides with the recipients, although specific tasks and activities will be shared among the recipient&nbsp;and the NIH Project Scientist.</p><p>NIH support of this study is contingent upon adequate participant recruitment based on the Recipient's Milestone Accrual Plan submitted at the time of funding.</p><p>The recipient is expected to demonstrate best effort compliance. Failure to achieve minimally acceptable milestone recruitment levels may result in the withholding future support and or negotiating an orderly close-out of this study.</p><p>NIH staff will act as a resource and facilitator for activities of the recipient&nbsp;with non-HCS researchers and other NIH, DHHS, or other federally-sponsored research networks that may be relevant to this effort.</p><p>Serve as a resource to provide scientific/programmatic support during the accomplishment of the clinical trial by participating in the design of the activities, advising in the selection of sources or resources, advising in management and technical performance, or participating in the preparation of publications.</p><p>Participate in the monitoring of issues relating to recruitment, retention and follow-up of study participants, and monitoring of data integrity and quality control through consideration of the annual reports, site visits, patient logs, etc. This review may include, but is not limited to, compliance with the study protocol, meeting patient enrollment targets, adherence to uniform data collection procedures, and the timeliness and quality of data reporting as needed to the administration and evaluation core.</p><p>Assist in the development and modification of study protocols.</p><p>NIH staff will interact with the PD(s)/PI(s) on a regular basis to monitor progress. Monitoring may include: regular communication with the PD(s)/PI(S) and his staff, periodic site visits for discussion with the recipients' research team, observation of field data collection and management techniques, fiscal reviews, and other relevant stewardship matters.</p><p>Additionally, an agency program official or IC program director will be responsible for the normal scientific and programmatic stewardship of the award and will be named in the award notice.</p><p><strong>Areas of Joint Responsibility include:</strong></p><p>The PD(s)/PI(s) provide, in concert with the NIH staff, support necessary to ensure that sites and investigators, and NIH and other research partners fully comply with federal regulatory requirements, including but not limited to those relating to human subjects protections, informed consent, and reporting of adverse events.</p><p>Recipients&nbsp;and NIH will jointly develop appropriate confidentiality procedures for data collection, processing, storage and analysis to ensure the confidentiality of data on individual health care provider organization patients, health care providers and other institutions.</p><p>All recipients&nbsp;and NIH will cooperate to ensure the timely and broad dissemination of lessons learned, to inform researchers and health care systems engaged in research in health care settings.</p><p><strong>Dispute Resolution:</strong></p><p>Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between recipients and the NIH may be brought to Dispute Resolution. A Dispute Resolution Panel composed of three members will be convened. It will have three members: a designee of the investigator chosen without NIH staff voting from among the PI of the FOA, one NIH designee, and a third designee with expertise in the relevant area who is chosen by the other two; in the case of individual disagreement, the first member may be chosen by the individual recipient. This special dispute resolution procedure does not alter the recipient's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulation 42 CFR Part 50, Subpart D and DHHS regulation 45 CFR Part 16.&nbsp;</p>
		</div>

	
		
	
	
		
		
		  		<div class="heading4" tabindex="0" data-element-id="220755" data-element-required="true" data-element-has-value="true" data-section-code="AAI" data-element-type="TEXT">
						<a id='_bookmark220755' tabindex='-1' aria-hidden='true'></a> 3. Data Management and Sharing 					
				</div>

		<div data-element-id="220755" data-element-has-label="true" data-element-required="true" data-element-has-value="true" data-section-code="AAI" data-element-type="TEXT">
			 <p>Consistent with the 2023 NIH Policy for Data Management and Sharing, when data management and sharing is applicable to the award, recipients will be required to adhere to the Data Management and Sharing requirements as outlined in the <a href="https://grants.nih.gov/grants/policy/nihgps/HTML5/section_8/8.2.3_sharing_research_resources.htm#Data">NIH Grants Policy Statement</a>. Upon the approval of a Data Management and Sharing Plan, it is required for recipients to implement the plan as described.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220756" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="AAI" data-element-type="TEXT">
			 
		</div>

	
		
	
	
		
		

		<div data-element-id="220757" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="AAI" data-element-type="TEXT">
			 <a id='_bookmark220757' tabindex='-1' aria-hidden='true'></a><h4>4. Reporting</h4><p>When multiple years are involved, recipients will be required to submit the&nbsp;<a href="//grants.nih.gov/grants/rppr/index.htm">Research Performance Progress Report (RPPR)</a>&nbsp;annually and financial statements as required in the <a href="https://grants.nih.gov/grants/policy/nihgps/HTML5/section_8/8.4.1_reporting.htm">NIH Grants Policy Statement Section 8.4.1 Reporting.</a>&nbsp;To learn more about post-award monitoring and reporting, see the NIH Grants &amp; Funding website, see <a href="https://grants.nih.gov/grants/guide/url_redirect.php?id=82428">Post-Award Monitoring and Reporting</a>.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220758" data-element-has-label="false" data-element-required="false" data-element-has-value="true" data-section-code="AAI" data-element-type="TEXT">
			 <a id='_bookmark220758' tabindex='-1' aria-hidden='true'></a><ul> </ul>
		</div>

	
		
	
	
		
		

		<div data-element-id="220759" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="AAI" data-element-type="TEXT">
			 
		</div>

	
		
	
	
		
		

		<div data-element-id="220760" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="AAI" data-element-type="TEXT">
			 <a id='_bookmark220760' tabindex='-1' aria-hidden='true'></a><p>A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=82420">NIH Grants Policy Statement Section 8.6 Closeout</a>. NIH NOFOs outline intended research goals and objectives. Post award, NIH will review and measure performance based on the details and outcomes that are shared within the RPPR, as described at 2 CFR Part 200.301.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220762" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="AC" data-element-type="TEXT">
			 <a id='_bookmark220762' tabindex='-1' aria-hidden='true'></a><a name="_Section VII. Agency Contacts"></a><h2>Section VII. Agency Contacts</h2>
		</div>

	
		
	
	
		
		

		<div data-element-id="220763" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="AC" data-element-type="TEXT">
			 <a id='_bookmark220763' tabindex='-1' aria-hidden='true'></a><p>We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.</p>
		</div>

	
		
	
	
		
		
		  		<div class="heading4" tabindex="0" data-element-id="220764" data-element-required="true" data-element-has-value="true" data-section-code="AC" data-element-type="TEXT">
						<a id='_bookmark220764' tabindex='-1' aria-hidden='true'></a>Application Submission Contacts 					
				</div>

		<div data-element-id="220764" data-element-has-label="true" data-element-required="true" data-element-has-value="true" data-section-code="AC" data-element-type="TEXT">
			 <p>eRA Service Desk (Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threaten&nbsp;submission by the due date, and post-submission issues)</p><p>Finding Help Online:&nbsp;<a href="https://www.era.nih.gov/need-help">https://www.era.nih.gov/need-help</a>&nbsp;(preferred method of contact)<br>Telephone: 301-402-7469 or 866-504-9552 (Toll Free)</p><p>General Grants Information (Questions regarding application instructions, application processes, and NIH grant resources)<br>Email:&nbsp;<a href="/cdn-cgi/l/email-protection#561124373822251f38303916383f3e78313920"><span class="__cf_email__" data-cfemail="763104171802053f18101936181f1e58111900">[email&#160;protected]</span></a>&nbsp;(preferred method of contact)<br>Telephone: 301-480-7075</p><p>Grants.gov Customer Support&nbsp;(Questions regarding Grants.gov registration and Workspace)<br>Contact Center Telephone: 800-518-4726<br>Email:&nbsp;<a href="/cdn-cgi/l/email-protection#3f4c4a4f4f504d4b7f584d5e514b4c11585049"><span class="__cf_email__" data-cfemail="3c4f494c4c534e487c5b4e5d52484f125b534a">[email&#160;protected]</span></a></p>
		</div>

	
		
	
	
		
		
		  		<div class="heading4" tabindex="0" data-element-id="220765" data-element-required="true" data-element-has-value="true" data-section-code="AC" data-element-type="TEXT">
						<a id='_bookmark220765' tabindex='-1' aria-hidden='true'></a>Scientific/Research Contact(s) 					
				</div>

		<div data-element-id="220765" data-element-has-label="true" data-element-required="true" data-element-has-value="true" data-section-code="AC" data-element-type="TEXT">
			 <p>Drew Townsend, Ph.D.<br>National Institute on Drug Abuse (NIDA)<br>Telephone: 301-443-4577<br>Email: <a href="/cdn-cgi/l/email-protection#9afee8ffedb4eef5edf4e9fff4fedaf4f3f2b4fdf5ec"><span class="__cf_email__" data-cfemail="761204130158021901180513181236181f1e581119">[email&#160;protected]</span></a></p><p>Ivan D. Montoya, M.D., M.P.H.<br>National Institute on Drug Abuse (NIDA)<br>Telephone: 301-827-5936<br>Email: <a href="/cdn-cgi/l/email-protection#93fafefcfde7fceaf2d3fef2faffbdfdfafbbdf4fce5"><span class="__cf_email__" data-cfemail="076e6a686973687e66476a666e6b29696e6f29606871">[email&#160;protected]</span></a></p>
<p>Evan Herrmann, Ph.D.<br>National Institute on Drug Abuse (NIDA)<br>Telephone: (301) 827-6406<br>Email: <a href="/cdn-cgi/l/email-protection#e88d9e8986c6808d9a9a85898686a8868180c68f879e"><span class="__cf_email__" data-cfemail="127764737c3c7a7760607f737c7c527c7b7a3c757d64">[email&#160;protected]</span></a></p>
		</div>

	
		
	
	
		
		
		  		<div class="heading4" tabindex="0" data-element-id="220767" data-element-required="true" data-element-has-value="true" data-section-code="AC" data-element-type="TEXT">
						<a id='_bookmark220767' tabindex='-1' aria-hidden='true'></a>Peer Review Contact(s) 					
				</div>

		<div data-element-id="220767" data-element-has-label="true" data-element-required="true" data-element-has-value="true" data-section-code="AC" data-element-type="TEXT">
			 <p>NIDA Review<br>
National Institute on Drug Abuse (NIDA)<br>
Email: <a href="/cdn-cgi/l/email-protection#e7a9aea3a6b7828295b582918e8290a7898e8fc9808891"><span class="__cf_email__" data-cfemail="a8e6e1ece9f8cdcddafacddec1cddfe8c6c1c086cfc7de">[email&#160;protected]</span></a></p>
		</div>

	
		
	
	
		
		
		  		<div class="heading4" tabindex="0" data-element-id="220769" data-element-required="true" data-element-has-value="true" data-section-code="AC" data-element-type="TEXT">
						<a id='_bookmark220769' tabindex='-1' aria-hidden='true'></a>Financial/Grants Management Contact(s) 					
				</div>

		<div data-element-id="220769" data-element-has-label="true" data-element-required="true" data-element-has-value="true" data-section-code="AC" data-element-type="TEXT">
			 <p>Chief Grants Management Officer<br>
National Institute of Drug Abuse (NIDA)<br>
Email: <a href="/cdn-cgi/l/email-protection#46282f2227212b24232b272f2a06282f222768282f2e68212930"><span class="__cf_email__" data-cfemail="a0cec9c4c1c7cdc2c5cdc1c9cce0cec9c4c18ecec9c88ec7cfd6">[email&#160;protected]</span></a>
 </a></p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220771" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="OTI" data-element-type="TEXT">
			 <a id='_bookmark220771' tabindex='-1' aria-hidden='true'></a><a name="_Section VIII. Other Information"></a><h2>Section VIII. Other Information</h2>
		</div>

	
		
	
	
		
		

		<div data-element-id="220772" data-element-has-label="false" data-element-required="true" data-element-has-value="true" data-section-code="OTI" data-element-type="TEXT">
			 <a id='_bookmark220772' tabindex='-1' aria-hidden='true'></a><p>Recently issued trans-NIH <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11163">policy notices</a> may affect your application submission. A full list of policy notices published by NIH is provided in the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11164">NIH Guide for Grants and Contracts</a>. All awards are subject to the terms and conditions, cost principles, and other considerations described in the <a href="//grants.nih.gov/grants/guide/url_redirect.php?id=11120">NIH Grants Policy Statement</a>.</p>
		</div>

	
		
	
	
		
		
		  		<div class="heading4" tabindex="0" data-element-id="220773" data-element-required="true" data-element-has-value="true" data-section-code="OTI" data-element-type="TEXT">
						<a id='_bookmark220773' tabindex='-1' aria-hidden='true'></a> Authority and Regulations 					
				</div>

		<div data-element-id="220773" data-element-has-label="true" data-element-required="true" data-element-has-value="true" data-section-code="OTI" data-element-type="TEXT">
			 <p>Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.</p>
		</div>

	
		
	
	
		
		

		<div data-element-id="220774" data-element-has-label="false" data-element-required="false" data-element-has-value="false" data-section-code="OTI" data-element-type="TEXT">
			 
		</div>
				</div>
		</div> <!-- end row -->
	</div>
<script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>


		</div>
	</div>


<div class="row">
  <div class="col-xs-12">
    <P>
    <HR>
    <A HREF="/grants/guide/WeeklyIndex.cfm?01-03-25">Weekly TOC for this Announcement</A><br>
    <A HREF="/grants/guide/index.html">NIH Funding Opportunities and Notices</A>
    <hr>
  </div>
</div>




<div class="row">
  <div class="col-md-4"> <a href="/grants/oer.htm"><img src="/images7/nih-oer-logo.jpg" alt="NIH Office of Extramural Research Logo" usemap="#Map2" border="0"></a>
    <map name="Map2" id="Map2">
      <area shape="rect" coords="89,17,359,39" href="http://www.nih.gov" />
      <area shape="rect" coords="91,39,286,58" href="https://grants.nih.gov/grants/oer.htm" />
      <area shape="rect" coords="3,5,78,55" href="https://grants.nih.gov/grants/oer.htm" />
    </map>
  </div>

  <div class="col-md-4">
    <div style="float:left; padding: 5 5 5 70"> <a href="https://www.hhs.gov/"><img src="/images7/dhhs_sm.gif" width="36" height="37" border="0" alt="Department of Health and Human Services (HHS) - Home Page" long desc="Logo, circular in shape, depicting an American eagle in-flight with stylized profiles of human faces appearing on the trailing edge of the wings. The perimeter of the logo is encircled with the words 'Department of Health and Human Services U S A'"></a></div>
    <div style="padding: 5 5 5 5;">Department of Health<br>
      and Human Services (HHS)</div>
  </div>

  <div class="col-md-4">
    <div style="padding: 5 5 5 0" align="center"> <a href="https://www.usa.gov/"><img src="/images7/USA_Gov_logo.gif" border="0" alt="USA.gov - Government Made Easy" long desc="Logo,- the words 'USA.gov - Government Made Easy' with single streaking star above the logo"></a> </div>
  </div>
</div>


<div class="row">
  <div class="col-xs-12" align="center" style="padding: 20 5 5 5"> <span style="color:#6E6E6E; font-size:1.0em; font-family: 'Trebuchet MS', Arial, Helvetica, sans-serif">NIH... Turning Discovery Into Health<sup>&reg;</sup></span> </div>
</div>


<div class="row">
  <div class="col-xs-12" align="center">
    
  </div>
</div>

</div> 

</BODY>
</HTML>